Drugs / Hezkue
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07231185 | Jan → Mar 2026 overdue | erectile dysfunction | Aspargo Labs, Inc | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-24 | Aspargo Labs, Inc | Regulatory Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands aspargolabs.com ↗
Aspargo Laboratories, Inc. (“Aspargo”), a privately held specialty pharmaceutical company focused on commercializing innovative formulations of leading tablet medications, announced today that the German Federal Institute for Drugs and Medical Devices has authorized the marketability of “Hezkue™ 12.5 mg per actuation, oral suspension“ in Germany effective as of January 12, 2023. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-24 | Aspargo Labs, Inc | Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands aspargolabs.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hezkue | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231185 ↗ |
| Route | Oral | “Hezkue® is an oral liquid formulation of sildenafil administered on an on-demand basis for the treatment period.” NCT07231185 ↗ |